Nykode Therapeutics AS Company Description

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases.

The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer.

Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Nykode Therapeutics AS

Country	Norway
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	136
CEO	Michael Engsig

Contact Details

Address: Oslo Research Park Oslo, 0349 Norway
Phone	47 22 95 81 93
Website	nykode.com

Stock Details

Ticker Symbol	NYKD
Exchange	Oslo Børs
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	NO0010714785
SIC Code	2836

Key Executives

Name	Position
Michael Thyring Engsig	Chief Executive Officer
Dr. Agnete B. Fredriksen Ph.D.	Co-Founder and Chief Scientific Officer
Harald Gurvin	Chief Financial Officer
Ulrich Blaschke	Chief Technology Officer
Louise Stubbe	Chief Legal Officer